Head and Neck Cancer, Head and Neck Neoplasms
Conditions
Keywords
head, neck, cancer, neoplasm
Brief summary
The primary objective of the first phase is to determine the safety, the maximum tolerated dose (MTD) and dose-limiting toxicity of TNFerade in combination with the previously studied combination of Fluorouracil (5FU), Hydroxyurea (HU) and standard daily radiotherapy in patients with recurrent head and neck cancer (RHNC). All chemoradiotherapy is administered on a week-on/week-off schedule. The primary objective of the second phase II is to determine the locoregional control rate at 24 months.
Interventions
Sponsors
GenVec
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Head and neck cancer * Patients must have a locoregional tumor amenable to reirradiation with curative intent. * disease, or the majority of disease, should be accessible to injection via direct intratumoral injection * Life expectancy of greater than 12 weeks * Age \> 18 years * ECOG performance status 0-1
Exclusion criteria
* Metastatic disease * History of malignancy (other than head and neck cancer) in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient * Patients may not be receiving any other investigational agents currently or within the 4 weeks prior to study Day 1 * Active infection of any type * Chronic treatment for greater than 6 months with steroids * Pregnant or lactating women * Patients with known history of cerebral vascular disease; stroke or TIA within the last 6 months * Patients with history of documented thrombosis (PE or DVT), or known coagulopathy or thrombophilia, or evidence of DVT / thromboembolic event upon enrollment * Patients receiving hormone replacement therapy or hormonal contraceptives within two weeks of day 1 * Patients who have undergone surgery within the last 1 month prior to day 1 * Patients with active carotid artery involvement or status post carotid artery graft / stenting
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| locoregional control at 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Locoregional control at 3, 6 and 12 months, as well as tumor response rate, progression-free survival at 3, 6, 12 and 24 months, and the rate of metastases at 3, 6, 12 and 24 months will also be assessed. | — |
Countries
United States
Outcome results
None listed